Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Sterenczak, Katharina A ^a   Meier, Martin ^c   Glage, Silke ^c   Meyer, Matthias ^c   Willenbrock, Saskia ^a   Wefstaedt, Patrick ^a   Dorsch, Martina ^c   Bullerdiek, Jörn ^a,b   Escobar, Hugo M ^a   Hedrich, Hans ^c   Nolte, Ingo ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MANGANESE CHLORIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RESEARCH; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHLORIDES; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MANGANESE COMPOUNDS; MICE; MICE, INBRED NOD; MICE, SCID; PROSTATIC NEOPLASMS;

EID: 84863594840     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-284     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians 2011, 61(2):69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC No. 10. Lyon 2010, International Agency for Research on Cancer, France, Available from: http://globocaniarcfr 2008.
3. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J Urol 2005, 173(2):342-359. 10.1097/01.ju.0000141580.30910.57, 15643172.
4. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines-part 2. J Urol 2005, 173(2):360-372. 10.1097/01.ju.0000149989.01263.dc, 15643173.
5. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate 2008, 68(6):629-639. 10.1002/pros.20726, 18213636.
6. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, Tindall DJ. Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998, 36(1):64-67. 10.1002/(SICI)1097-0045(19980615)36:1<64::AID-PROS12>3.0.CO;2-G, 9650919.
7. Fan TM, de Lorimier LP. Tumors of the male reproductive system. Withrow and MacEwen's Small Animal Clinical Oncology 2007, 637-648. Saunders, St Louis, Withrow SJ, Vail DM, 4.
8. Waters DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res 1997, 17(3A):1467-1470.
9. Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). Journal of the American Veterinary Medical Association 1991, 199(11):1623-1630.
10. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate 2000, 45(2):173-183. 10.1002/1097-0045(20001001)45:2<173::AID-PROS12>3.0.CO;2-R, 11027417.
11. Johnston SD, Kamolpatana K, Root-Kustritz MV, Johnston GR. Prostatic disorders in the dog. Anim Reprod Sci 2000, 60-61:405-415.
12. Leroy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Vet J 2009, 180(2):149-162. 10.1016/j.tvjl.2008.07.012, 18786842.
13. Winkler S, Murua Escobar H, Eberle N, Reimann-Berg N, Nolte I, Bullerdiek J. Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype. J Hered 2005, 96(7):782-785. 10.1093/jhered/esi085, 15994418.
14. Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, Dorsch M, Reimann-Berg N, Hedrich HJ, Bullerdiek J, Nolte I. Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC cancer 2008, 8:240. 10.1186/1471-2407-8-240, 2527616, 18706092.
15. Eaton CL, Pierrepoint CG. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate 1988, 12(2):129-143. 10.1002/pros.2990120204, 3368402.
16. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001, 46(1):2-10. 10.1002/1097-0045(200101)46:1<2::AID-PROS1002>3.0.CO;2-5, 11170126.
17. LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006, 66(11):1213-1222. 10.1002/pros.20408, 16683269.
18. Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, Rosol TJ. Development of a brain metastatic canine prostate cancer cell line. Prostate 2011, 71(12):1251-1263.
19. Bernsen MR, Moelker AD, Wielopolski PA, van Tiel ST, Krestin GP. Labelling of mammalian cells for visualisation by MRI. Eur Radiol 2009, 20(2):255-274.
20. Himmelreich U, Hoehn M. Stem cell labeling for magnetic resonance imaging. Minim Invasive Ther Allied Technol 2008, 17(2):132-142. 10.1080/13645700801969873, 18465447.
21. Bulte JW. In vivo MRI cell tracking: clinical studies. Ajr 2009, 193(2):314-325. 10.2214/AJR.09.3107, 2857985, 19620426.
22. Liu W, Frank JA. Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol 2009, 70(2):258-264. 10.1016/j.ejrad.2008.09.021, 2680943, 18995978.
23. Chung J, Yamada M, Yang PC. Magnetic resonance imaging of human embryonic stem cells. Current protocols in stem cell biology 2009, 10:5A.3.1-5A.3.9.
24. Huang HC, Chang PY, Chang K, Chen CY, Lin CW, Chen JH, Mou CY, Chang ZF, Chang FH. Formulation of novel lipid-coated magnetic nanoparticles as the probe for in vivo imaging. J Biomed Sci 2009, 16:86. 10.1186/1423-0127-16-86, 2758848, 19772552.
25. Rodriguez O, Fricke S, Chien C, Dettin L, VanMeter J, Shapiro E, Dai HN, Casimiro M, Ileva L, Dagata J, Johnson MD, Lisanti MP, Koretsky A, Albanese C. Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle 2006, 5(1):113-119. 10.4161/cc.5.1.2295, 16340310.
26. Koretsky AP, Silva AC. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 2004, 17(8):527-531. 10.1002/nbm.940, 15617051.
27. Silva AC, Lee JH, Aoki I, Koretsky AP. Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. NMR Biomed 2004, 17(8):532-543. 10.1002/nbm.945, 15617052.
28. Wendland MF. Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to imaging of the heart. NMR Biomed 2004, 17(8):581-594. 10.1002/nbm.943, 15761947.
29. Silva AC, Bock NA. Manganese-enhanced MRI: an exceptional tool in translational neuroimaging. Schizophr Bulletin 2008, 34(4):595-604.
30. Gimi B, Leoni L, Desai T, Magin RL, Roman BB. Imaging of pancreatic beta cell function by Mn2+- enhanced MRI. 2002, 18-24. Hawaii convention center, Honolulu, Hawaii, May 2002.
31. Aoki I, Takahashi Y, Chuang KH, Silva AC, Igarashi T, Tanaka C, Childs RW, Koretsky AP. Cell labeling for magnetic resonance imaging with the T1 agent manganese chloride. NMR Biomed 2006, 19(1):50-59. 10.1002/nbm.1000, 16411253.
32. Yamada M, Yang P. In vitro labeling of human embryonic stem cells for magnetic resonance imaging. J Vis Exp 2008, (17): . 10.3791/827, 22825033.
33. Yamada M, Gurney PT, Chung J, Kundu P, Drukker M, Smith AK, Weissman IL, Nishimura D, Robbins RC, Yang PC. Manganese-guided cellular MRI of human embryonic stem cell and human bone marrow stromal cell viability. Magn Reson Med 2009, 62(4):1047-1054. 10.1002/mrm.22071, 19526508.
34. Sotak CH, Sharer K, Koretsky AP. Manganese cell labeling of murine hepatocytes using manganese(III)-transferrin. Contrast media & molecular imaging 2008, 3(3):95-105. 10.1002/cmmi.235, 22915493.
35. Na HB, Lee JH, An K, Park YI, Park M, Lee IS, Nam DH, Kim ST, Kim SH, Kim SW, Lim KH, Kim KS, Kim SO, Hyeon T. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem 2007, 46(28):5397-5401. International ed.
36. Gilad AA, Walczak P, McMahon MT, Na HB, Lee JH, An K, Hyeon T, van Zijl PC, Bulte JW. MR tracking of transplanted cells with " positive contrast" using manganese oxide nanoparticles. Magn Reson Med 2008, 60(1):1-7. 10.1002/mrm.21622, 2575033, 18581402.
37. Himmelreich U, Dresselaers T. Cell labeling and tracking for experimental models using magnetic resonance imaging. Methods 2009, 48(2):112-124. San Diego, Calif, 10.1016/j.ymeth.2009.03.020, 19362150.
38. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, Gerig G. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. NeuroImage 2006, 31(3):1116-1128. 10.1016/j.neuroimage.2006.01.015, 16545965.